Hejing Bao1,2, Ling Zhen Ma1, Chengzhu Zhao1, Mengge Yu1, Baishen Zhang3, Juan Zhang4, Guibao Peng5, Xiaotong Lin6, Yinhua Fang7, Hehong Bao2, Shudong Ma8. 1. Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China. 2. Department of Oncology, Chongqing University Three Gorges Hospital/Chongqing Three Gorges Central Hospital, Chongqing, 404100, China. 3. Department of Oncology, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China. 4. Department of Otorhinolaryngology, Zhujiang Hospital, Southern Medical University, 253 Gongye Road, Guangzhou, 510282, Guangdong, China. 5. Department of General Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 6. Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. 7. Department of Emergency, Chongqing Banan District People's Hospital, Chongqing, 401320, China. 8. Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China. mashudong@aliyun.com.
Abstract
PURPOSE: Primary pulmonary lympho-epithelioma-like carcinoma (PPLELC) is a rare subtype of primary non-small cell lung cancer (NSCLC). Currently, there is still lack of research data on anti-angiogenic therapy of advanced PPLELC. The purpose of this study was to investigate the efficacy and safety of anti-angiogenic therapy combined with chemotherapy compared with traditional chemotherapy for these patients. METHODS: Advanced PPLELC patients admitted to six grade A hospitals from January 2013 to January 2021 were selected. The patients received anti-angiogenic therapy combined with chemotherapy (AT group) or chemotherapy (CT group) alone. RESULTS: A total of 65 patients were included in this study, including 31 patients in the AT group treated with anti-angiogenic therapy combined with chemotherapy and 34 patients in the CT group treated with chemotherapy alone. As of October 1, 2021, the median progression-free survival (PFS) in the AT group was 11.2 months [95% confidence interval (CI), 5.9-16.5]. The median PFS in the CT group was 7.0 months [95%CI, 5.1-8.9] [Hazard Ratio (HR), 0.49; 95%CI, 0.29-0.83; P = 0.008]. The 1-year PFS rates were 41.9% and 17.6%, respectively. The overall response rates (ORR) of two groups were 45.2% (95% CI, 0.27-0.64), 38.2% (95% CI, 0.21-0.56), (P = 0.571). The disease control rates (DCR) of two groups were 93.5% (95% CI, 0.84-1.03), 88.2% (95% CI, 0.77-1.00), (P = 0.756). CONCLUSION: Among patients with advanced PPLELC, the PFS of patients with anti-angiogenic therapy combined with chemotherapy is better than that of patients with chemotherapy alone. Anti-angiogenic therapy combined with chemotherapy is an optional treatment scheme.
PURPOSE: Primary pulmonary lympho-epithelioma-like carcinoma (PPLELC) is a rare subtype of primary non-small cell lung cancer (NSCLC). Currently, there is still lack of research data on anti-angiogenic therapy of advanced PPLELC. The purpose of this study was to investigate the efficacy and safety of anti-angiogenic therapy combined with chemotherapy compared with traditional chemotherapy for these patients. METHODS: Advanced PPLELC patients admitted to six grade A hospitals from January 2013 to January 2021 were selected. The patients received anti-angiogenic therapy combined with chemotherapy (AT group) or chemotherapy (CT group) alone. RESULTS: A total of 65 patients were included in this study, including 31 patients in the AT group treated with anti-angiogenic therapy combined with chemotherapy and 34 patients in the CT group treated with chemotherapy alone. As of October 1, 2021, the median progression-free survival (PFS) in the AT group was 11.2 months [95% confidence interval (CI), 5.9-16.5]. The median PFS in the CT group was 7.0 months [95%CI, 5.1-8.9] [Hazard Ratio (HR), 0.49; 95%CI, 0.29-0.83; P = 0.008]. The 1-year PFS rates were 41.9% and 17.6%, respectively. The overall response rates (ORR) of two groups were 45.2% (95% CI, 0.27-0.64), 38.2% (95% CI, 0.21-0.56), (P = 0.571). The disease control rates (DCR) of two groups were 93.5% (95% CI, 0.84-1.03), 88.2% (95% CI, 0.77-1.00), (P = 0.756). CONCLUSION: Among patients with advanced PPLELC, the PFS of patients with anti-angiogenic therapy combined with chemotherapy is better than that of patients with chemotherapy alone. Anti-angiogenic therapy combined with chemotherapy is an optional treatment scheme.
Authors: Virginia Di Paolo; Marta Colletti; Valentina Ferruzzi; Ida Russo; Angela Galardi; Iside Alessi; Giuseppe Maria Milano; Angela Di Giannatale Journal: Curr Med Chem Date: 2020 Impact factor: 4.530
Authors: Maria Raffaella Ambrosio; Bruno Jim Rocca; Monica Onorati; Vasileios Mourmouras; Maria Grazia Mastrogiulio; Sergio Crispino; Concetta Liberatore; Rosa Santopietro Journal: Int J Surg Pathol Date: 2010-05-05 Impact factor: 1.271